Management of patients with atopic dermatitis undergoing systemic therapy during COVID‐19 pandemic in Italy: Data from the DA‐COVID‐19 registry
- Autori: Chiricozzi, Andrea; Talamonti, Marina; De Simone, Clara; Galluzzo, Marco; Gori, Niccolò; Fabbrocini, Gabriella; Marzano, Angelo Valerio; Girolomoni, Giampiero; Offidani, Annamaria; Rossi, Maria Teresa; Bianchi, Luca; Cristaudo, Antonio; Fierro, Maria Teresa; Stingeni, Luca; Pellacani, Giovanni; Argenziano, Giuseppe; Patrizi, Annalisa; Pigatto, Paolo; Romanelli, Marco; Savoia, Paola; Rubegni, Pietro; Foti, Caterina; Milanesi, Nicola; Belloni Fortina, Anna; Bongiorno, Maria Rita; Grieco, Teresa; Di Nuzzo, Sergio; Fargnoli, Maria Concetta; Carugno, Andrea; Motolese, Alberico; Rongioletti, Franco; Amerio, Paolo; Balestri, Riccardo; Potenza, Concetta; Micali, Giuseppe; Patruno, Cataldo; Zalaudek, Iris; Lombardo, Maurizio; Feliciani, Claudio; Di Nardo, Lucia; Guarneri, Fabrizio; Peris, Ketty; Caldarola, Giacomo; Silvaggio, Dionisio; Dattola, Annunziata; Napolitano, Maddalena; Ferrucci, Silvia Mariel; Dal Bello, Giacomo; Bianchelli, Tommaso; Rovati, Chiara; Pigliacelli, Flavia; Ortoncelli, Michela; Hansel, Katharina; Calabrese, Giulia; Loi, Camilla; Iannone, Michela; Veronese, Federica; Romita, Paolo; Tronconi, Greta; Caroppo, Francesca; Tilotta, Giovanna; Sernicola, Alvise; Esposito, Maria; Raponi, Francesca; Gualdi, Giulio; Rech, Giulia; Musumeci, Maria Letizia; Nisticò, Steven Paul; Campitiello, Alessio; Bonzano, Laura; Piras, Viviana
- Anno di pubblicazione: 2021
- Tipologia: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/509886
Abstract
Background Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic.Methods A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity.Results A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred.Conclusions Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.